Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call

Oppenheimer analyst Jay Olson recently raised his price target on Viking Therapeutics (NASDAQ: VKTX) stock to $120 from $100 and maintained an outperform rating. Given that the stock price at the time of writing is merely $28. 50, hitting the price target would represent a quadrupling in the share price.